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24-28 January, 1998 
Angiogenesis and cancer, Hyatt 
Orlando, Orlando, FL. 
Contact: American Association for 
Cancer Research, Public Ledger 
Building, Suite 826, 150 South 
Independence Mall West, Philadelphia, 
PA 19106-3483, USA. 
Tel: +l 21.5 440 9300 
Fax:+12154409313 
e-mail: webmaster@aacr.org 
http://www.aacr.org/confrnc.htm 
3-5 February, 1998 
Exploiting molecular diversity: 
combinatorial libraries for drug 
discovery, San Diego. 
Contact: Cambridge Healthtech Inst., 
1037 Chestnut St, Newton Upper Falls, 
MA 02164, USA. 
Tel: +1 617 630 1300 
Fax: +l 617 630 132.5 
4-6 February, 1998 
ComTech 98: 2nd annual European 
conference on combinatorial 
technologies, Montreux, Switzerland. 
Contact: Scitec SA, Av. De Provence 20, 
Lausanne 20, Switzerland, CH-1000. 
Tel: +41 21 626 4630 
Fax: +41 21 624 15 49 
e-mail: symposia@worldcom.ch 
http://www.scitec-robotics.com 
6-7 February, 1998 
Molecular recognition in drug design: 
docking and scoring, San Francisco. 
Contact: Kristina Clarke, University of 
California San Francisco, Department of 
Pharmaceutical Chemistry, PO Box 0446, 
San Francisco, CA 94143-0446, USA. 
Tel: +1415 476 1913 
Fax: +1415 502 4690 
e-mail: kristina@cgl.ucsf.edu 
http://mdi.ucsf.edu 
15-20 February, 1998 
1998 Gordon research conference on 
the chemistry & biology of peptides, 
Ventura, CA. 
http://www.caltech.edu/-biweblpeptides 
grc98.html 
22-24 February, 1998 
Miniturization technologies - practical 
applications in high throughput 
screening and combinatorial 
chemistry, Lake Tahoe, CA. 
Contact: IBC USA Conferences, Inc., 
225 Turnpike Road, Southborough, MA 
01772-1749, USA. 
Tel: +l 508 481-6400 
Fax: +l 508 481-7911 
e-mail: inq@ibcusa.com 
http://www.ibcusa.com/conf/miniature/ 
index.html 
2-4 March, 1998 
5th Annual exploiting molecular 
diversity: small molecule libraries for 
drug discovery, Coronado, CA. 
Contact: Cambridge Healthtech 
Institute, 1037 Chestnut Street, Newton 
Upper Falls, MA, USA. 
Tel: +1617 630 1300 
Fax: + 1 617 630 1325 
e-mail: chi@healthtech.com 
http://www.healthcech.com/conferences/ 
5-6 March, 1998 
3rd Annual high throughput organic 
synthesis: developing small molecule 
libraries, Coronado, CA. 
Contact: Cambridge Healthtech 
Institute, 1037 Chestnut Street, Newton 
Upper Falls, MA 02164, USA. 
Tel: + 1 617-630 1300 
Fax : + 1 617-630 1325 
e-mail: chi@healthtech.com 
http://www.healthtech.com/conferences/ 
2 l-24 March, 1998 
ABRF ‘98. From genome to function - 
technical challenges of the post- 
genome era, San Diego, CA. 
Contact: ABRF Meeting Office, 9650 
Rockville Pike, Bethesda, 
MD 20814-3998, USA. 
Tel: +l 301530 7010 
Fax: +1301 530 7014 
e-mail: abrf98Qfaseb.org 
http://www.faseb.orgJmeetings/abrf/ 
abrf98/abrfmp,htm 
28 March-3 April, 1998 
Keystone symposium on nuclear 
receptor gene family, Incline Village, 
Nevada. 
Contact: Keystone Symposia, Drawer 
1630, Silverthorne, CO 80498, USA. 
Tel: 800 253 0685 or +1 970 262 1230 
Fax: +1 970 262 1525, 
e-mail: keystone@symposia.com 
28 March-3 April, 1998 
Angiogenesis and vascular 
remodelling, Steamboat Springs, 
Colorado. 
Contact: Keystone Symposia, Drawer 
1630, Silverthorne, CO 80498, USA. 
Tel: 800 253-0685 or +1 970 262 1230 
Fax: +l 970 262 1525 
e-mail: keystone@symposia.com 
29 March-2 April, 1998 
215th American chemists society 
national meeting, Dallas, Texas. 
Contact: American Chemical Society 
Meetings Department, 1155 Sixteenth 
Street, N.W. Washington, D.C. 20036, 
USA. 
Tel: +1 202 872 4396 
Fax: +1 202 872 6128 
e-mail: natlmtgs@acs.org 
5-9 April, 1998 
Triennial meeting of the nucleic acids 
and molecular biology group of the 
RSC and Biochemical Society - 
NACON-IV, Sheffield, UK. 
Contact: Drs J Grasby and M Blackburn, 
Department of Chemistry, University of 
Sheffield, Sheffield 53 7HF, UK. 
Tel: +44 (0)114 222 9462, 
Fax: +44 (0)114 273 8673 
e-mail: j.a.&asby@sheffield.ac.uk or 
g.m.blackburn@sheffield.ac.uk 
20-21 April, 1998 
IBC’s Seventh annual international 
conference: high-throughput 
screening, Wyndham Emerald Plaza 
Hotel, San Diego, CA. 
Contact: IBC USA Conferences, Inc., 
225 Turnpike Road, Southborough, MA 
017721749, USA. 
Tel: +1 508 4816400 
Fax: +l 508 481 7911 
e-mail: 791 linq@ibcusa.com 
http://www.ibcusa.com/conf/screeningJ 
index.html 
8-10 May, 1998 
5th Conference on metal ions in 
medicine and biology, Munich, Germany. 
Contact: Dr V Negretti di Bratter, Hahn 
Meitner Institut Berlin, Glienicker Str. 
100, Berlin, Germany, D-14109 
Fax: + 49 030 8062 2781 
e-mail: negretti@hrni.de 
http://www.hmi.de/bereiche/N/NG/ 
Events.html 
13-17 May, 1998 
18th Blankanese conference - 
orphan receptors and novel ligands, 
Hamburg-Blankanese, Germany. 
Contact: Dr D Richter, Institut fur 
Zellbiochemie, UKE, Martinistr. 52, 
20246 Hamburg, Germany. 
Fax: +49 40 4717 4541 
e-mail: richter@uke.uni-hamburg.de 
16-20 May, 1998 
American society for biochemistry & 
molecular biology annual meeting, 
Washington, DC. 
http://www.faseb.orgJmeetings/asbmb/ 
asbmb98/asbmbcfp.html 
3-7 May, 1998 
Proteins that bind RNA, Avalon, NJ. 
Contact: Mrs Helen F Pirrello, 
Department of Molecular Biology and 
Biochemistry, Rutgers, The State 
University of New Jersey, Center for 
Advanced Biotechnology and Medicine, 
679 Hoes Lane, Piscataway, NJ 08855- 
1179, USA. 
Tel: +l 732 235 4962 
Fax: +l 732 235 4880 
e-mail: pirrello@mbcl.rutgers.edu, 
http://cpmcnet.columbia:edu/www/ 
protRNAmtg 
14-18 June, 1998 
Proteases and protease inhibitors in 
cancer, Nyborg Strand Conference 
Center, Fyn, Denmark. 
Contact: American Association for 
Cancer Research, Public Ledger 
Building, Suite 826, 150 South 
Independence Mall West, Philadelphia, 
PA 19106-3483, USA. 
Tel: +1 215 440 9300 
Fax: +l 215 440 9313 
e-mail: webmastefiaacrorg 
http://www.aacr,org/confrnc.htm 
14-19 June, 1998 
Gordon research conference on 
bioorganic chemistry, Proctor 
Academy, Andover, New Hampshire, 
USA. 
http://www.grc.uri.edu/98sched.htm 
28 June-3 July, 1998 
1998 Reaction mechanisms 
conference, Asilomar Conference 
Center, Carmel, CA. 
Contact: Angel Kim, Department of 
Chemistry & Biochemistry UCLA, 405 
Hilgard Avenue, Los Angeles, CA 
90095-1569 USA. 
Tel: +1310 206 1036 
Fax: +1310 206 3722 
http://www.chem.ucla.edu/conf/ 
reaction.html 
l-4 July, 1998 
2nd European symposium on 
antimicrobial agents, Hradec Kralove, 
Czech Republic. 
Contact: Antimicrobial Symposium 
Secretariat, Dept. of Inorganic and 
Organic Chemistry, Faculty of 
Pharmacy, Charles University, 
Heyrovskeho 1203, Hradec Kralove, 500 
05 Czech Republic. 
Tel: + 420 49 5210002 
Fax: + 420 49 5067343 
e-mail: palat@faf.cuni.cz 
http://www.faf.cuni.cz/antimicr/ 
12-17 July, 1998 
Chemistry and biology of 
tetyrapyrroles - Gordon research 
conference, Newport, RI, USA. 
Contact: Gordon Research Conferences, 
University of Rhode Island, PO. Box 
984, West Kingston, Rhode Island 
02892-0984, USA. 
Tel: + 1401 783-4011 
Fax + 1401 783-7644 
e-mail: grc@grcmail.grc.uri,edu 
http://www.grc.uri.edu/progra-2 
/tetra.htm 
9-14 August, 1998 
XIX International carbohydrate 
symposium, San Diego, USA. 
Contact: ICS 98 Symposium Secretariat, 
Department of Chemistry, 516 Physical 
Sciences 1, University of California, 
Irvine, CA 926972025, USA 
Tel: +1 714 824 8976 
Fax: +l 714 824 1372 
e-mail: ics98Quci.edu 
http://www.ics98.uci.edu 
23-27 August, 1998 
216th American chemists society 
national meeting, Boston, 
Massachusetts. 
Contact: American Chemical Society 
Meetings Department, 1155 Sixteenth 
Street, N.W. Washington, D.C. 20036, 
USA. 
Tel: +l 202 872 4396 
Fax: +1 202 872 6128 
e-mail: natlmtgs@acs.org 
6- 10 September, 1998 
Thirteenth international round table: 
nucleosides, nucleotides and their 
biological applications, Montpellier, 
France. 
Contact: Drs Gilles Gosselin and 
Bernard Rayner, Universite 
MontpellierII, Case courrier 008, 
Sciences et Techniques du Languedoc, 
Place Eugene Bataillon, 34095 
Montpellier Cedex 5, France. 
Tel: + 33 04 67 14 38 55 
Fax: + 33 04 67 04 20 29 
e-mail: irt@univ-montpZ.fr 
R21 
A selection of interesting papers 
published last month in Chemistry 
& Biology’s sister journals, Current 
Biology, Folding & Design and 
Structure, chosen and summarized 
by the staff of Chemistry & Biology. 
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0 An IQGAP-related protein 
controls actin-ring formation 
and cytokinesis in yeast. 
J Andrew Epp and John Chant (1997). 
Cm Biol. 7, 921-929. 
Proteins of the IQGAP family have been 
identified as candidate effecters for the 
Rho family of GTPases; however, little 
is known about their cellular functions. 
The domain structures of IQGAP family 
members make them excellent 
candidates as regulators of the 
cytoskeleton: their sequences include an 
actin-binding domain homologous to 
that found in calponin, IQ motifs for 
interaction with calmodulin, and a 
GTPase-binding domain. The genomic 
sequence of Sacct?aron2yces cer-evisiae 
revealed a single gene encoding an 
IQGAP family member (denoted 
IQGAP-related protein: Iqgl). Iqgl and 
IQGAPs share similarity along their 
entire length, with an amino-terminal 
calponin-homology (CH) domain, IQ 
repeats, and a conserved carboxyl 
terminus. In contrast to IQGAPs, Iqgl 
lacks an identifiable GAP motif, a WW 
domain, and IR repeats, although the 
functions of these domains in IQGAPs 
are not well defined., Deletion of the 
ZQCl gene resulted in lethality. Cellular 
defects included a deficiency in 
cytokinesis, altered actin organization, 
aberrant nuclear segregation, and cell 
lysis. Consistent with a role in 
cytokinesis, Iqgl co-localizes with an 
actin ring encircling the mother-bud 
neck late in the cell cycle - a putative 
cytokinetic ring. IQGI overexpression 
resulted in premature actin-ring 
formation, suggesting that Iqgl activity 
temporally controls formation of this 
structure during the cell cycle. Yeast 
IQGAP-related protein, Iqgl, is an 
important regulator of cellular 
morphogenesis, inducing actin-ring 
formation in association with cytokinesis. 
31 October 1997, Research Paper, 
Current Biology 
0 Interphase chromosomes 
undergo constrained diffusional 
motion in living cells. 
WF Marshall, A Straight, JF Marko, J 
Swedlow, A Dernburg, A Belmont, 
AW Murray, DA Agard and JW Sedat 
(1997). Cur. Biol. 7, 930-939. 
Structural studies of fixed cells have 
revealed that interphase chromosomes 
are highly organized into specific 
arrangements in the nucleus, and have 
led to a picture of the nucleus as a static 
structure with immobile chromosomes 
held in fixed positions, an impression 
apparently confirmed by recent photo- 
bleaching studies. Functional studies of 
chromosome behavior, however, suggest 
that many essential processes, such as 
recombination, require interphase 
chromosomes to move around within the 
nucleus. To reconcile these contradictory 
views, the authors exploited methods for 
tagging specific chromosome sites in 
living cells of Saccharomyces cereuisiae 
with green fluorescent protein and in 
Drosophila melanogaster with 
fluorescently labeled topoisomerase II. 
Combining these techniques with 
submicrometer single-particle tracking, 
the motion of interphase chromatin was 
directly measured. The authors found 
that chromatin does indeed undergo 
significant diffusive motion within the 
nucleus, but this motion is constrained 
such that a given chromatin segment is 
free to move within only a limited 
subregion of the nucleus. Chromatin 
diffusion was found to be insensitive to 
metabolic inhibitors, suggesting that it 
results from classical Brownian motion 
rather than from active motility. 
Nocodazole greatly reduced chromatin 
confinement, suggesting a role for the 
cytoskeleton in the maintenance of 
nuclear architecture. The constrained 
diffusion of chromatin is consistent with 
a highly defined nuclear architecture, 
but also allows enough motion for 
processes requiring chromosome 
motility to take place. 
5 November 1997, Research Paper, 
Current Biology 
0 Atm-dependent interactions of a 
mammalian Chkl homolog with 
meiotic chromosomes. 
G Flaggs, AW Plug, KM Dunks, 
KE Mundt, JC Ford, MRE Quiggle, 
EM Taylor, CH Westphal, T Ashley, 
MF Hoekstra and AM Carr (1997). 
Cm-r. Biol. 7, 977-986. 
Checkpoint pathways prevent cell-cycle 
progression in the event of DNA lesions. 
Checkpoints are well defined in mitosis, 
where lesions can be the result of 
extrinsic damage, and they are critical in 
meiosis, where DNA breaks are a 
programmed step in meiotic 
recombination. In mitotic yeast cells, the 
Chkl protein couples DNA repair to the 
R22 Chemistry & Biology 1998, Vol 5 No 1 
cell-cycle machinery. The Atm and Atr 
proteins are mitotic cell-cycle proteins 
that also associate with chromatin during 
meiotic prophase I. The genetic and 
regulatory interaction between Atm and 
mammalian Chkl appears to be 
important for integrating DNA-damage 
repair with cell-cycle arrest. The authors 
have identified structural homologs of 
yeast Chkl in human and mouse. 
ChklHUmo has protein kinase activity 
and is expressed in the testis. Chkl 
accumulates in late zygotene and 
pachytene spermatocytes and is present 
along synapsed meiotic chromosomes. 
The association of Chkl with meiotic 
chromosomes and levels of Chkl protein 
depend upon a functional Atm gene 
product, but Chkl is not dependent 
upon p53 for meiosis I functions. 
Mapping of CHKl to human chromo- 
somes indicates that the gene is located 
at 1 lq22-23, a region marked by 
frequent deletions and loss of hetero- 
zygosity in human tumors. The Atm- 
dependent presence of Chkl in mouse 
cells and along meiotic chromosomes, 
and the late pachynema co-localization 
of Atr and Chkl on the unsynapsed axes 
of the paired X and Y chromosomes 
suggest that Chkl acts as an integrator 
for Atm and Atr signals and may be 
involved in monitoring the processing of 
meiotic recombination. Furthermore, 
mapping of the CHKI gene to a region of 
frequent loss of heterozygosity in human 
tumors at 1 lqZ?--23 indicates that the 
CHKl gene is a candidate tumor 
suppressor gene. 
12 November 1997, Research Paper, 
Current Biology 
0 Association of a phosphatidyl- 
inositol-specific 3-kinase with a 
human Pans-Golgi network 
resident protein. 
DM Hickinson, JM Lucocq, MC Towler, 
S Clough, J James, SR James, CP 
Downes and S Ponnambalam (1997). 
Cm Biol. 7, 987-990. 
The eukaryotic trans-Golgi network 
(TGN) is a key site for the formation of 
transport vesicles destined for different 
intracellular compartments. A key 
marker for the mammalian TGN is 
TGN38/46. This integral membrane 
glycoprotein cycles between the TGN 
and the cell surface and is implicated in 
recruitment of cytosolic factors and 
regulation of at least one type of vesicle 
formation at the mammalian TGN. 
q A novel receptor for 
Apo2lJTRAIL contains a 
truncated death domain. 
SA Marsters, JP Sheridan, RM Pitti, A 
Huang, M Skubatch, D Baldwin, J Yuan, 
A Gurney, AD Goddard, P Godowski 
and A Ashkenazi (1997). CUK Biol. 7, 
1003-l 006. 
ApoZ ligand (ApoZL, also called TRAIL 
for tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand) belongs to 
the TNF family and activates apoptosis 
in tumor cells. Three closely related 
receptors bind ApoZL: DR4 and DR5, 
which contain cytoplasmic death 
domains and signal apoptosis, and DcRl, 
a decoy receptor that lacks a cytoplasmic 
tail and inhibits ApoZL function. By 
cross-hybridization with DcRl, the 
The authors have identified a 
phosphatidylinositol (PtdIns)-specific 
3-kinase activity associated with the 
human orthologue (TGN46), which is , 
sensitive to lipid kinase inhibitors. n 
Treatment of HeLa cells with low 
levels of these inhibitors reveals subtle 
morphological changes in TGN46- 
positive compartments. These findings 
suggest a role for PtdIns 3-kinases and 
presumably for the product, PtdIns 3- 
phosphate, in the formation of 
secretory transport vesicles by 
mechanisms conserved in yeast and 
mammals. 
29 September 1997, Brief 
Communication, Current Biology 
authors have identified a fourth Apo2L 
receptor, which contains a cytoplasmic 
region with a truncated death domain. 
This protein was named decoy receptor 
2 (DcR2). The DcR2 gene mapped to 
human chromosome 8~21, as did the 
genes encoding DR4, DR5 and DcRl. A 
single D&2 mRNA transcript showed a 
unique expression pattern in human 
tissues. Upon overexpression, DcR2 did 
not activate apoptosis or nuclear factor- 
KB but it substantially reduced cellular 
sensitivity to Apo2L-induced apoptosis. 
The results suggest that DcRZ functions 
as an inhibitory Apo2L receptor. 
6 October 1997, Brief Communication, 
Current Biology 
0 Favorable domain size in 
proteins. 
Dong Xu and Ruth Nussinov (1997). 
fold. Des. 3, 1 l-l 7. 
It has been observed that single-domain 
proteins and domains in multidomain 
Elsewhere in biology R23 
proteins favor a chain length in the range 
loo-150 amino acids. To understand the 
origin of the favored size, the authors 
constructed an empirical function for the 
free energy of unfolding versus the chain 
length. The parameters in the function 
are derived by fitting to the energy of 
hydration, entropy and enthalpy of 
unfolding of nine proteins. This energy 
function cannot be used to calculate the 
energetics accurately for individual 
proteins because the energetics also 
depend on other factors but the energy 
function statistically characterizes the 
general relationship between the free 
energy of unfolding and the size of the 
protein. The predicted optimal number 
of residues, which corresponds to the 
maximum free energy of unfolding, is 
100, in agreement with a statistical 
analysis of protein domains derived from 
IL’ n 
their experimental structures. This study 
shows that the energetic balance is the 
dominant factor governing protein size 
and forces a large protein to break into 
several domains during folding. 
27 November 1997, Research Paper, 
Folding and Design 
0 Solution structure and proposed 
binding mechanism of a novel 
potassium channel toxin 
Ic-conotoxin PVIIA. 
Martin J Scanlon, David Naranjo, Linda 
Thomas, Paul F Alewood, Richard J 
Lewis and David J Craik (1997). 
Structure 5, 1585-l 597. 
K-PVIIA is a 27 residue polypeptide 
isolated from the venom of C&US 
p~~pzlrascens and is the first member of a 
new class of conotoxins that block 
potassium channels. In comparison to 
other ion channels of eukaryotic cell 
membranes, voltage-sensitive potassium 
channels are relativelysimple and 
methodology has been developed for 
mapping their interactions with small- 
peptide toxins. PVIIA, therefore, is a 
valuable new probe of potassium channel 
structure. This study of the solution 
structure and mode of channel binding of 
PVIIA forms the basis for mapping the 
interacting residues at the conotoxin-ion 
channel interface. The three-dimensional 
structure of PVIIA resembles the triple- 
stranded p sheet/cystine-knot motif 
formed by a number of toxic and 
inhibitory peptides. Subtle structural 
differences are observed between PVIIA 
and other conotoxins with similar 
structural frameworks, however. Electro- 
physiological binding data suggest that 
PVIIA blocks channel currents by 
binding in a voltage-sensitive manner to 
the external vestibule and occluding the 
pore. Comparison of the electrostatic 
surface of PVIIA with that of the well- 
characterised potassium channel blocker 
charybdotoxin suggests a likely binding 
orientation for PVIIA. On the basis of a 
comparison of the structures of PVIIA 
and charybdotoxin, the authors suggest 
that Lys19 of PVIIA is the residue which 
is responsible for physically occluding 
the pore of the potassium channel. 
15 December 1997, Research Paper, 
Structure 
Cl Staurosporine-induced 
conformational changes of 
cAMP-dependent protein 
kinase catalytic subunit explain 
inhibitory potential. 
Lars Prade, Richard A Engh, Andreas 
Girod, Volker Kinzel, Robert Huber and 
Dirk Bossemeyers (1997). Structure 5, 
1627-l 637. 
Staurosporine inhibits most protein 
kinases at low concentrations. As most 
tyrosine kinases are either proto 
oncoproteins or are involved in oncogenic 
signaling, the development of protein 
kinase inhibitors is a goal of cancer 
research. Staurosporine and many of its 
derivatives are being tested as anticancer 
drugs. To understand the mode of 
inhibition of staurosporine to protein 
kinases, the molecule was co-crystallized 
with the catalytic subunit of CAMP- 
dependent protein kinase. The crystal 
K19 
R22 
structure of the protein kinase catalytic 
subunit with staurosporine bound to the 
adenosine pocket shows considerable 
induced-lit rearrangement of the enzyme 
and a unique open conformation. The 
inhibitor mimics several aspects of 
adenosine binding and induces 
conformational changes of neighboring 
enzyme residues. The results explain the 
high inhibitory potency of staurosporine, 
and also illustrate the flexibility of the 
protein kinase active site. The structure 
is not only useful for the design of 
improved anticancer therapeutics and 
signaling drugs, but also provides a 
deeper understanding of the confor- 
mational flexibility of the protein kinase. 
15 December 1997, Research Paper, 
Structure 
0 The loop E-loop D region of 
Escherichia co/i 5s rRNA: the 
solution structure reveals an 
unusual loop that may be 
important for binding ribosomal 
proteins. 
Anne Dallas and Peter B Moore (1997). 
Structure 5, 1639-l 653. 
5s ribosomal RNA is the smallest 
rRNA. Its Watson-Crick helices were 
R24 Chemistry & Biology 1998, Vol 5 No 1 
identified more than 20 years ago, but 
the conformations of its loops have long 
defied analysis. One of the three arms of 
5S rRNA, residues 69-106 in Eschrichia 
co& contains a 14-residue internal loop 
called loop E. The sequence of loop E 
is conserved within kingdoms, and is 
terminated by a pyrimidine-rich loop 
called loop D. Loop E is the binding 
site for the ribosomal protein L25 in the 
E. coli ribosome. The solution structure 
of a 42 nucleotide derivative of E. coli 
5s rRNA that includes loops D and E 
has been determined by nuclear 
magnetic resonance spectroscopy. This 
structure rationalizes all the biochemical 
and chemical protection data available 
for the loop E-loop D arm of intact 5s 
rRNA. While the molecule is double 
helical over its entire length, the 
geometry of its internal loop is highly 
irregular, and its irregularities may 
explain why the loop E-loop D arm of 
55 rRNA interacts specifically with 
ribosomal protein L25 in E. coli. 
15 December 1997, Research Paper, 
Structure 
0 Unusual ligand structure in 
Ni-Fe active center and an 
additional Mg site in 
hydrogenase revealed by high 
resolution X-ray structure 
analysis. 
Yoshiki Higuchi, Tatsuhiko Yagi and 
Noritake Yasuoka (1997). Structure 5, 
1671-l 680. 
The hydrogenase of Desulfoai&o sp. 
catalyzes the reversible oxidoreduction 
of molecular hydrogen, in conjunction 
with a specific electron acceptor, 
cytochrome cs. The Ni-Fe active center 
of Desulfovibrio hydrogenase has an 
unusual ligand structure with non- 
protein ligands. An atomic model at high 
resolution is required to make concrete 
assignment of the ligands which 
coordinate the Ni-Fe center. These in 
turn will provide insight into the 
mechanism of electron transfer during 
the reaction catalysed by hydrogenase. 
The X-ray structure of the hydrogenase 
from Desulfovibrio vzltgaris Miyazaki has 
been solved. The overall folding pattern 
and the spatial arrangement of the metal 
centers are very similar to those found in 
Deswljbvibrio gigas hydrogenase. This 
crystal structure enabled the authors to 
assign the non-protein ligands to the Fe 
atom in the Ni-Fe site and revealed the 
presence of a Mg center, located 
approximately 13 A from the Ni-Fe 
active center. From the nature of the . 
electron-density map, stereochemical. 
geometry and atomic parameters of the 
refined structure, the most probable 
candidates for the four ligands, 
coordinating the Ni-Fe center, have 
been proposed to be diatomic S=O, GO 
and C=N molecules and one sulfur 
atom. These ligands may have a role as 
an electron sink during the electron 
transfer reaction between the 
hydrogenase and its biological 
counterparts, and they could stabilize 
the redox state of Fe(II), which may not 
change during the catalytic cycle and is 
independent of the redox transition of 
the Ni. The hydrogen-bonding system 
between the Ni-Fe and the Mg centers 
suggests the possible involvement of the 
Mg center in the reaction cycles of 
hydrogen metabolism. 
15 December 1997, Research Paper, 
Structure 
q New ingights into the regulation 
of the blood clotting cascade 
derived from the X-ray crystal 
structure of bovine 
meizothrombin des Fl in 
complex with PPACK 
Philip D Martin, G Malkowski, Jeffrey 
Box, Charles T Emson and Brian FP 
Edwards (1997). Structure 5, 
1681-l 693. 
The conversion of prothrombin to 
thrombin by factor Xa is the 
penultimate step in the blood clotting 
cascade. In &JO, where the conversion 
occurs primarily on activated platelets in 
association with factor Va and Ca2+ ions, 
meizothrombin is the major 
intermediate of the two step reaction. 
Meizothrombin rapidly loses the 
fragment 1 domain (Fl) by autolysis to 
‘become meizothrombin des Fl 
(mzTBN-Fl). The physiological 
properties of mzTBN-Fl differ 
dramatically from those of thrombin due 
to the presence of prothrombin 
fragment 2 (FZ), which remains 
covalently attached to the activated 
thrombin domain in mzTBN-Fl. The 
crystal structure of mzTBN-Fl has been 
determined by molecular replacement, 
using only the thrombin domain. The 
protease active site was inhibited with 
D-Phe-Pro-Arg-chloromethylketone 
(PPACK) to reduce autolysis. The 
mobile linker chain connecting the so- 
called kringle and thrombin domains 
and the first two N-acetylglucsoamine 
residues attached to the latter were seen 
in the electron-density maps. The F’Z 
kringle domain in mzTBN-Fl is bound 
to the electropositive heparin-binding 
site on thrombin in an orientation that is 
systematically shifted and has 
significantly more interdomain contacts 
compared to a noncovalent complex of 
free F2 and free thrombin. F2 in 
mzTBN-Fl forms novel hydrogen 
bonds to the carbohydrate chain of 
thrombin and perhaps stabilizes a 
unique, rigid conformation of the 
y-autolysis loop through non-local 
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effects. The F2 linker chain, which does 
not interfere with the active site or 
fibrinogen-recognition site, is arranged 
so that the two sites cleaved by factor 
Gla domain 
Xa are separated by 36 A. The two 
mzTBN-Fl molecules in the 
asymmetric unit share a tight ‘dime? 
contact in which the active site of one 
molecule is partially blocked by the F2 
kringle domain of its partner. This 
interaction suggests a new model for 
prothrombin organization. 
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